The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status

Abstract Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor that plays a carcinogenic role in breast cancer (BC) through gene amplification, mutation, or overexpression. Traditional methods of HER2 detection were divided into positive (immunohistochemistry (IHC) 3+/fluorescence in situ hybridization (FISH) amplification) and negative (IHC 2+/FISH−, IHC 1+, IHC 0) according to the dichotomy method. Anti‐HER2‐targeted therapies, such as trastuzumab and pertuzumab, have significantly improved the prognosis of HER2‐positive patients. However, up to 75% to 85% of patients remain HER2‐negative. In recent years, with the rapid development of molecular biology, gene detection technology, targeted therapy, and immunotherapy, researchers have actively explored the clinicopathological characteristics, molecular biological characteristics, treatment methods, and HER2 detection methods of HER2‐low/zero breast cancer. With the clinical efficacy of new anti‐HER2 targeted drugs, accurate classification of breast cancer is very important for the treatment choice. Therefore, the following review summarizes the necessity of developing HER2 detection methods, and the clinicopathological and drug treatment characteristics of patients with HER2‐low/zero, to light the dawn of the treatment of breast cancer patients with HER2‐low/zero expression.